welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.

expertly curated content related to this topic
-
Francis A. Farraye, MD, MScDr. Farraye is Clinical Director in the ...
-
Luca Stocchi, MDLuca Stocchi is a Surgeon and Chair in t...
-
Familial Adenomatous Polyposis in Pediatrics: Natural History, Emerging Surveillance and Management Protocols, Chemo...Familial adenomatous polyposis (FAP) is ...
-
Young Adult Cancer ConnectionYoung Adult Cancer Connection, co-founde...
-
Medizinische Universitätsklinik KnappschaftskrankenhausThe Knappschaftskrankenhaus is affiliate...
-
Mayo ClinicPatient Resources: Colon ...
-
Impact of a Hospital-based Register on the Management of Familial Adenomatous PolyposisColorectal cancer in familial adenomatou...